Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222423 · ClinicalTrials.gov registry record
A Study of the Epidemiology and Hospital Management of Patients With PROS in France
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 3,605
- Enrollment target
NCT07222423: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07222423 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,605 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222423 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 3,605 participants
- Enrollment target
Study Summary
The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from the French National Hospitals Database, Programme de Médicalisation des Systèmes d'Information (PMSI). The study period was from January 2015 to December 2022.
Primary Outcome
Yearly prevalence rate was calculated by dividing the number of identified patients with PROS by the total French population during the inclusion period. The inclusion period was from January 2017 to December 2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,605 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2024-10-08 |
What the finished NCT07222423 record still lists
NCT07222423 is an observational study that tracks outcomes without assigning an intervention. Its 3,605 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07222423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07222423 about?
NCT07222423 is a clinical study titled "A Study of the Epidemiology and Hospital Management of Patients With PROS in France". The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from t...
What is the current status of trial NCT07222423?
This trial is currently completed. The enrollment target is 3,605 participants. The study started on 2024-01-15. Estimated completion is 2024-10-08.
Who is sponsoring clinical trial NCT07222423?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
- NCT07091032 · 3,600 participants · NA
Building Connections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI